SEC Form 4 · accession 0001005201-18-000017
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur J Higgins
Officer — Director, President and CEO · Director
Period of report
Dec 1, 2018
Accepted (ET)
Dec 4, 2018 · 11:05 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 1, 2018 | M | 34,861 | $0.00 | A | 54,621 | D | |
| Common StockF1 | Dec 1, 2018 | F | 10,215 | $4.99 | D | 44,406 | D | |
| Common Stock | holding | — | — | — | 3,000 | I | By Child | |
| Common Stock | holding | — | — | — | 90,000 | I | By Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4,F2,F3 | — | Dec 1, 2018 | M | 34,861 | D | — | Dec 1, 2020 | Common Stock | 34,861 | 69,720 | D |
Explanation of responses
- F1Represents shares of common stock withheld for payment of taxes upon the vesting of restricted stock units.
- F2Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock
- F3These restricted stock units are scheduled to vest 25% on December 1, 2017, 25% on December 1, 2018, 25% on December 1, 2019 and 25% on December 1, 2020.
- F4The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.